1- Integrative Oncology Department, Breast Cancer Research Center, Motamed Cancer Institute, ACECR, Tehran, Iran
2- Reproductive Biotechnology Research Center, Avicenna Research Institute, ACECR, Tehran, Iran
3- Integrative Oncology Department, Breast Cancer Research Center, Motamed Cancer Institute, ACECR, Tehran, Iran & Reproductive Biotechnology Research Center, Avicenna Research Institute, ACECR, Tehran, Iran , k.gilany@avicenna.ac.ir
Abstract: (10 Views)
Oncometabolites such as L-lactate, succinate, fumarate, R-2-hydroxyglutarate, kynurenine, and itaconate are emerging as pivotal drivers of cancer progression. Beyond their metabolic roles, these molecules function as signaling mediators that remodel epigenetic landscapes, reprogram the tumor microenvironment, and promote immune evasion. This review synthesizes current insights into their biochemical origins, oncogenic mechanisms, and therapeutic potential, highlighting how targeting oncometabolite-driven pathways could facilitate the development of novel cancer therapies.
Select article type:
Review Article |
Subject:
Molecular Mechanisms Received: 2025/11/1 | Accepted: 2025/12/9 | ePublished: 2026/02/14